The global Preimplantation Genetic Testing (PGT) market, a key component of modern IVF and fertility treatments, is set to grow significantly, according to a report from ResearchAndMarkets.com. The market, valued at $852.35 million in 2024, is projected to reach $1.28 billion by 2030, growing at a compound annual growth rate of 7.10%. This growth is driven by advances in testing technologies like Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), and Fluorescence In Situ Hybridization (FISH), and increased awareness of genetic diseases. The report also highlights the role of PGT in reducing genetic disease risks in newborns and mitigating selective pregnancy termination risks. While Europe led the global PGT market in 2024, the Asia-Pacific region is expected to witness the highest growth rate.